Evaluation of a Rapid Screening Test for Detection of Adenovirus in Tears
Launched by RAPID PATHOGEN SCREENING · Dec 16, 2005
Trial Information
Current as of May 16, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical Study Enrollment Criteria
- Upon completing the in-vitro studies, a perspective, blinded clinical study was started. Patients who were older than 1 month of age, seen within 7 days of developing a red eye, and who demonstrate at least one criterion from two out of the three categories below were included:
- • I. History: 1) Spread from one eye to the other several days later, 2) recent or concurrent upper respiratory symptoms within the preceding two weeks, 3) or an exposure to someone with "pink eye" within the preceding three weeks
- • II. Symptoms: 1) Tearing, 2) mucoid or purulent discharge, 3) eye lash matting, 4) burning, 5) itching, or 6) foreign body sensation
- • III. Signs: 1) An inferior palpebral conjunctival reaction with \> or = 1+ papillary or follicular reactions, 2) presence of a preauricular node
- Exclusion Criteria:
- • Patients with associated skin vesicles, corneal dendrites, traumatic corneal abrasion, concurrent corneal ulcers, foreign bodies, ocular pemphigoid, trauma, previous history of chemical/thermal injury to eyes or eyelids (anytime in past), or greater than trace intraocular inflammation were excluded from the study. Additionally, patients with allergy to corn starch, talcum powder, or dacron were also be excluded. Patients using any topical ophthalmic medication (i.e. antibiotics) were required to wait at least 30 minutes from their last dose prior to device application and wait at least 2 hours after their last dose of any ointment application
About Rapid Pathogen Screening
Rapid Pathogen Screening is a pioneering clinical trial sponsor dedicated to advancing the field of infectious disease diagnostics. With a focus on developing innovative screening technologies, the organization aims to enhance the speed and accuracy of pathogen detection, thereby improving patient outcomes and public health responses. Leveraging cutting-edge methodologies and a commitment to rigorous scientific evaluation, Rapid Pathogen Screening collaborates with healthcare institutions and research entities to facilitate clinical trials that address critical gaps in pathogen surveillance. Through its initiatives, the sponsor strives to deliver timely and reliable solutions that empower clinicians and health authorities in the fight against infectious diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Denver, Colorado, United States
Springfield, Missouri, United States
Erlangen, , Germany
Homburg, , Germany
Patients applied
Trial Officials
Elisabeth J Cohen, MD
Principal Investigator
Wills Eye Hospital
Shachar Tauber, MD
Principal Investigator
St Johns Ophthalmology Clinic, Springfield, MO
Frank Schirra, MD
Principal Investigator
Universitätsklinikum des Saarlandes, Klinik für Augenheilkunde, Homburg, Germany
Kristian Kozich, MD
Principal Investigator
University of Erlangen-Nurnberg, Erlangen, Germany
Richard Davidson, MD
Principal Investigator
University of Colorado Health Science Center, Denver, CO
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials